Introduction
============

Worldwide, breast cancer accounts for 15% of all cancer deaths in women.[@b1-cmar-10-6649] Although early detection through mammography, improved diagnostic technology, and improved treatments have evolved,[@b2-cmar-10-6649] the prevalence of breast cancer continues to rise in many parts of the world, including South America, Africa, and Asia,[@b3-cmar-10-6649] and mortality from breast cancer remains a global issue.[@b4-cmar-10-6649]

The RecQ family of DNA helicases is one of the most highly conserved groups of helicases throughout evolution and is necessary for the stability of the whole genome.[@b5-cmar-10-6649] In humans, five RecQ-helicase proteins have been recognized: RECQL, BLM, WRN, RECQL4, and RECQL5. There are three conserved regions in human RecQ proteins: the helicase domain, the RecQ carboxy-terminal (RQC) domain, and the helicase and RNase DC-terminal (HRDC) domain. Most of the DNA-helicase superfamily utilizes energy derived from ATP hydrolysis to unwind dsDNA, including secondary DNA structures, and some helicases also influence protein--DNA complexes.[@b6-cmar-10-6649] RecQ helicases bind to and translocate along one DNA strand in a 3′→5′ direction, and ssDNA stimulates their dsDNA-unwinding activity. RecQ helicases separate double-stranded nucleic acids, and are essential for every aspect of DNA metabolism, including recombination, replication, and DNA repair.[@b7-cmar-10-6649]

Mutations in *BLM*, *WRN*, or *RECQL4*, located on chromosomes 15q26.1, 8p12 and 8q24.3 respectively, were found to be associated with some diseases in humans.[@b8-cmar-10-6649] Less clear is whether dysregulation of RecQ-family expression is related to an increased risk of cancer. RECQL is over-expressed in multiple myeloma and associated with poor prognosis,[@b9-cmar-10-6649] and the expression of RECQL is correlated with tumorigenesis in breast cancer.[@b10-cmar-10-6649] Recent studies also showed that abnormal expression of the BLM protein might lead to the development of malignant tumors,[@b11-cmar-10-6649]--[@b13-cmar-10-6649] while overexpression of BLM stimulates DNA injury and induces sensitivity to cisplatin chemotherapy in triple-negative breast cancer.[@b14-cmar-10-6649] WRN is considered a tumor suppressor, and it has been shown to inhibit tumor growth in nude mouse xenograft models of breast cancer.[@b15-cmar-10-6649] RECQL4 is overexpressed in breast cancer cell lines, and depletion of RECQL4 facilitates apoptosis.[@b16-cmar-10-6649] Arvind et al assessed RECQL5 expression in breast cancers, and found that expression levels of RECQL5 were associated with aggressive phenotypes and poor survival outcomes.[@b17-cmar-10-6649] The prognostic roles of each RecQ member, especially at the mRNA level, remain poorly understood in breast cancer.

Therefore, the aims of this study were to use an online Kaplan--Meier plotter database to investigate the prognostic role of mRNA expression of the five RecQ DNA-helicase family members -- *RECQL*, *BLM*, *WRN*, *RECQL4*, and *RECQL5* -- and clinical outcomes in women with breast cancer. We also confirmed the protein-expression levels of WRN and RECQL4 by immunohistochemistry (IHC) in breast cancer tissue.

Methods
=======

Use of online databases, including Kaplan--Meier Plotter
--------------------------------------------------------

The association of RecQ family member mRNA expression with prognostic value was analyzed using the online Kaplan--Meier Plotter breast cancer database (<http://kmplot.com/analysis/index.php>), which was produced using gene-expression data and survival information downloaded from the Gene Expression Omnibus (<http://www.ncbi.hlm.nih.gov/geo>).[@b18-cmar-10-6649]

Breast cancer patient-outcome data
----------------------------------

At the time of the study, the Kaplan--Meier Plotter database was capable of evaluating the effect of mRNA expression levels of 54,675 genes on patient survival using 10,641 cancer samples, which included breast cancer,[@b18-cmar-10-6649] ovarian cancer,[@b19-cmar-10-6649] lung cancer,[@b20-cmar-10-6649] and gastric cancer.[@b21-cmar-10-6649] There were 3,955 breast cancer patients with relapse-free survival (RFS) data, 1,402 with overall survival (OS) data, 1,747 with distant metastasis-free survival (DMFS) data, and 414 with postprogression survival (PPS) data. ER, PR, HER2, and lymph-node status, tumor grade, intrinsic breast-tumor subtype, and *TP53* gene-expression data were collected and analyzed.

Tissue microarrays (TMAs) and IHC staining
------------------------------------------

TMAs were purchased from Outdo Biotech (Shanghai, China), and contained 160 breast cancer samples. Detailed clinicopathological characteristics of breast cancer samples are provided in Table S1. Approval from the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine was obtained for the experiments. IHC staining of the TMAs was performed using primary antibodies against WRN (ab200; Abcam, Cambridge, UK) or RECQL4 (25470002; Novus Biologicals, Littleton, CO, US). Briefly, paraffin slides were baked at 60°C overnight, deparaffinized with 100% xylene, and rehydrated in graded ethanol. After antigen retrieval and inactivation of endogenous peroxidases, slides were preincubated in 10% normal goat serum and incubated with WRN (1:200) or RECQL4 (1:400) overnight at 4°C. Subsequently, slides were serially washed and incubated with biotinylated secondary antibody for 1 hour at room temperature. Finally, slides were stained with DAB and counterstained with hematoxylin.

WRN or RECQL4 expression in TMAs was blindly evaluated by two pathologists using the immunoreactivity score (IRS), based on both the percentage of positive cells and the intensity of staining. The percentage of positive cells was graded as follows: 0 (negative), 1 (\<10%), 2 (10%--50%), 3 (51%--80%), 4 (\>80%). The intensity of staining was graded as follows: 0 (no color reaction), 1 (mild reaction), 2 (moderate reaction), 3 (intense reaction). IRS ranging from 0 to 12 was calculated by multiplication of the two scores. In this study, WRN or RECQL4 expression was defined as low (IRS ≤6) or high (IRS \>6).

Data analysis
-------------

In this study, we entered five RecQ DNA-helicase family members (*RECQL*, *BLM*, *WRN*, *RECQL4*, and *RECQL5*) into the database (<http://kmplot.com/analysis/index.php?P=service%20&cancer%20=%20breast>) and analyzed them under different clinical parameters. We only selected the JetSet best probe set of five RecQ DNA-helicase family members to obtain Kaplan--Meier survival plots. mRNA expression of related genes above or below the median divides the cases into high and low expression, respectively. Associations between protein-expression levels of WRN or RECQL4 and clinicopathological features were analyzed using Pearson's χ^2^ test. In both Kaplan--Meier Plotter and prognostic relevance of WRN and RECQL4 protein levels in breast cancer patients, survival analysis was estimated according to the Kaplan--Meier method and log-rank test. HR and 95% CI were calculated using the Cox proportional-hazard regression model. *P*\<0.05 was considered statistically significant.

Results
=======

Prognosis in patients with breast cancer and mRNA expression of the five RecQ DNA-helicase family members
---------------------------------------------------------------------------------------------------------

Patient-survival data and mRNA expression of the five RecQ family members in breast cancer patients were obtained from [www.kmplot.com](http://www.kmplot.com). OS, DMFS, RFS, and PPS curves were plotted. The prognostic significance of *RECQL* mRNA expression was evaluated from the data obtained (Affymetrix ID for *RECQL*: 212918_at). Increased mRNA-expression levels of *RECQL* were significantly associated with reduced RFS (HR 1.28, 95% CI 1.15--1.42; *P*\<0.001; [Figure 1A](#f1-cmar-10-6649){ref-type="fig"}), and reduced PPS (HR 1.32, 95% CI 1.03--1.68; *P*=0.027; [Figure 1B](#f1-cmar-10-6649){ref-type="fig"}). However, mRNA-expression levels of *RECQL* were not significantly correlated with OS (HR 1.04, 95% CI 0.84--1.28; *P*=0.74) or DMFS (HR 1.06, 95% CI 0.87--1.28; *P*=0.57; [Figure 1C and D](#f1-cmar-10-6649){ref-type="fig"}).

The prognostic significance of *BLM* mRNA expression was evaluated from the data obtained (Affymetrix ID for *BLM*: 205733_at). Increased mRNA-expression levels of *BLM* were significantly associated with reduced DMFS (HR 1.28, 95% CI 1.06--1.56; *P*=0.011; [Figure 2A](#f2-cmar-10-6649){ref-type="fig"}). However, mRNA-expression levels of *BLM* were not significantly correlated with OS (HR 1.05, 95% CI 0.85--1.3; *P*=0.65), RFS (HR 1.02, 95% CI 0.91--1.13; *P*=0.76), or PPS (HR 1.18, 95% CI 0.92--1.5; *P*=0.19; [Figure 2B--D](#f2-cmar-10-6649){ref-type="fig"}).

The prognostic significance of *WRN* mRNA expression was evaluated from the data obtained (Affymetrix ID for *WRN*: 205667_at). Increased mRNA-expression levels of *WRN* were associated with improved patient OS (HR 0.76, 95% CI 0.61--0.94; *P*=0.011; [Figure 3A](#f3-cmar-10-6649){ref-type="fig"}) and increased RFS (HR 0.81, 95% CI 0.73--0.91; *P*\<0.001; [Figure 3B](#f3-cmar-10-6649){ref-type="fig"}). However, *WRN* mRNA expression was not significantly correlated with DMFS (HR 0.87, 95% CI 0.71--1.05; *P*=0.15) or PPS (HR 1.21, 95% CI 0.95--1.55; *P*=0.12; [Figure 3C and D](#f3-cmar-10-6649){ref-type="fig"}).

The prognostic significance of *RECQL4* mRNA expression was evaluated from the data obtained (Affymetrix ID for *RECQL4*: 213520_at). Increased mRNA-expression levels of *RECQL4* were significantly associated with reduced patient OS (HR 1.74, 95% CI 1.4--2.16; *P*\<0.001; [Figure 4A](#f4-cmar-10-6649){ref-type="fig"}), DMFS (HR 1.53, 95% CI 1.26--1.86; *P*\<0.001; [Figure 4B](#f4-cmar-10-6649){ref-type="fig"}), and RFS (HR 1.65, 95% CI 1.48--1.84; *P*\<0.001; [Figure 4C](#f4-cmar-10-6649){ref-type="fig"}). Also, high expression of *RECQL4* mRNA was modestly correlated with poor PPS (HR 1.27, 95% CI 0.99--1.62; *P*=0.055; [Figure 4D](#f4-cmar-10-6649){ref-type="fig"}), but not significantly.

The prognostic significance of *RECQL5* mRNA expression was evaluated from the data obtained (Affymetrix ID for *RECQL5*: 221686_s\_at). Increased mRNA-expression levels of *RECQL5* were significantly associated with increased RFS (HR 0.83, 95% CI 0.74--0.93; *P*\<0.001; [Figure 5A](#f5-cmar-10-6649){ref-type="fig"}), but not significantly correlated with patient OS (HR 0.98, 95% CI 0.79--1.21; *P*=0.84), DMFS (HR 1.07, 95% CI 0.88--1.3; *P*=0.47), or PPS (HR 1.04, 95% CI 0.82--1.33; *P*=0.72; [Figure 5B--D](#f5-cmar-10-6649){ref-type="fig"}).

Prognosis in patients with mRNA expression of the five RecQ DNA-helicase family members and intrinsic subtypes
--------------------------------------------------------------------------------------------------------------

To investigate the role of the five RecQ helicase family members further, the prognostic significance of each was evaluated with the different intrinsic breast cancer subtypes identified for patients in the database. The intrinsic subtypes included luminal A, luminal B, HER2-positive, and basal-like breast cancer. Expression levels of mRNA for *BLM* and *WRN* and the intrinsic breast cancer subtypes showed no significant prognostic associations ([Figures S1](#SD1-cmar-10-6649){ref-type="supplementary-material"} and [S2](#SD2-cmar-10-6649){ref-type="supplementary-material"}). Increased expression of *RECQL* mRNA was significantly associated with increased patient OS in patients with basal-like breast cancer (HR 0.54; 95% CI 0.32--0.91; *P*=0.019; [Figure 6A](#f6-cmar-10-6649){ref-type="fig"}). However, there was no significant difference in patient OS between patients with luminal A, luminal B, and HER2-positive type breast cancer ([Figure 6B--D](#f6-cmar-10-6649){ref-type="fig"}).

Increased expression levels of *RECQL4* mRNA were significantly associated with reduced OS in patients with intrinsic luminal A-type breast cancer (HR 2.26, 95% CI 1.56--3.27; *P*\<0.001; [Figure 7A](#f7-cmar-10-6649){ref-type="fig"}) and HER2-positive breast cancer (HR 2.2, 95% CI 1.12--4.31; *P*=0.019; [Figure 7B](#f7-cmar-10-6649){ref-type="fig"}). However, mRNA-expression levels of *RECQL4* were not significantly correlated with prognosis in patients with intrinsic luminal B or basal-like breast cancer subtypes ([Figure 7C, D](#f7-cmar-10-6649){ref-type="fig"}).

As shown in [Figure 8A](#f8-cmar-10-6649){ref-type="fig"}, increased expression levels of *RECQL5* mRNA were significantly associated with reduced patient OS (HR 2.09, 95% CI 1.05--4.17; *P*=0.032) in patients with HER2-positive breast cancer. However, expression levels of *RECQL5* mRNA were not significantly correlated with OS in patients with the other three intrinsic subtypes of breast cancer ([Figure 8B--D](#f8-cmar-10-6649){ref-type="fig"}).

Prognosis in patients with mRNA expression of the five RecQ DNA-helicase family members and patient clinicopathological characteristics
---------------------------------------------------------------------------------------------------------------------------------------

Patient clinicopathological characteristics included tumor ER status, PR status, positive lymph-node status, grade, and *TP53*-mutation status. Increased *RECQL4* mRNA expression was significantly correlated with reduced patient OS in ER-positive breast cancer (HR 1.9, 95% CI 1.33--2.74; *P*\<0.001), and increased *WRN* mRNA expression was moderately correlated with increased patient OS in ER-negative breast cancer (HR 0.64, 95% CI 0.4--1.02; *P*=0.056; [Table 1](#t1-cmar-10-6649){ref-type="table"}).

In patients with PR-positive breast cancer, only *RECQL4* mRNA expression was significantly associated with reduced patient prognosis (HR 4.87, 95% CI 1.01--23.52; *P*=0.029; [Table 2](#t2-cmar-10-6649){ref-type="table"}). As shown in [Table 3](#t3-cmar-10-6649){ref-type="table"}, high levels of *RECQL5* mRNA expression were associated with improved patient prognosis for patients with breast cancer who were lymph-node-negative (HR 0.68, 95% CI 0.47--0.99; *P*=0.043).

As shown in [Table 4](#t4-cmar-10-6649){ref-type="table"}, there was no significant correlation between mRNA-expression levels of the five RecQ DNA helicase family members and histopathological grades of the breast cancers. [Table 5](#t5-cmar-10-6649){ref-type="table"} shows that high expression levels of *RECQL* mRNA were significantly associated with favorable prognosis in mutant-p53-type breast cancer patients (HR 0.33, 95% CI 0.13--0.82; *P*=0.013).

Prognosis in patients with protein expression of WRN and RECQL4
---------------------------------------------------------------

To analyze the association between mRNA expression of RecQ family members and prognosis in breast cancer patients, we used the Kaplan--Meier Plotter database and found that high mRNA-expression levels of *WRN* were significantly associated with improved OS and high mRNA-expression levels of *RECQL4* significantly associated with reduced OS in patients with breast cancers. mRNA-expression levels of *RECQL*, *BLM*, and *RECQL5* were not significantly correlated with OS. Then, we investigated if WRN and RECQL4 protein levels were significantly associated with OS in breast cancer patients. We performed IHC in breast cancer TMAs.

As some cores within the TMAs were missing in the process of IHC staining, there were 152 of 160 tumor cores suitable for analysis of WRN protein expression and 147 of 160 tumor cores suitable for analysis of RECQL4 protein expression. [Figure 9A and B](#f9-cmar-10-6649){ref-type="fig"} show representative images of WRN-stained and RECQL4-stained TMAs. WRN and RECQL4 exhibited high expression rates in breast cancer tissue, with values of 44.1% (67 of 152) and 37.4% (55 of 147), respectively. Moreover, Kaplan--Meier analysis showed that high WRN protein expression was significantly associated with increased OS in breast cancer patients (*P*=0.031, [Figure 9C](#f9-cmar-10-6649){ref-type="fig"}) and patients with high RECQL4 levels displayed reduced OS (*P*=0.003, [Figure 9D](#f9-cmar-10-6649){ref-type="fig"}). The results suggested that at both mRNA and protein levels, high WRN expression was correlated with increased OS and high RECQL4 expression with reduced OS.

Discussion
==========

The aims of this study were to use a Kaplan--Meier plotter database to investigate the prognostic value of expression of the five RecQ DNA helicase family members -- *RECQL*, *BLM*, *WRN*, *RECQL4*, and *RECQL5* -- and clinical outcomes in women with breast cancer. The findings of the study showed that increased mRNA-expression levels of *RECQL* were significantly associated with reduced RFS and PPS in all breast cancers and improved OS in patients with basal-like breast cancer and mutant-p53-type breast cancer. Increased mRNA-expression levels of *BLM* were correlated with reduced DMFS in all patients. Increased mRNA-expression levels of *WRN* were significantly associated with improved OS and RFS in patients with breast cancers. High mRNA-expression levels of *RECQL4* were significantly associated with reduced OS, DMFS, and RFS in patients with breast cancers, and reduced OS in patients with luminal A-type breast cancer, HER2-positive breast cancer, ER-positive breast cancer, and PR-positive breast cancer. High mRNA-expression levels of *RECQL5* were associated with improved RFS in all breast cancer patients, including those with lymph-node-negative cancer, but with reduced OS in patients with HER2-positive breast cancer. IHC staining confirmed that high WRN expression was correlated with increased OS and high expression of RECQL4 associated with reduced OS, just as the results of mRNA levels showed. As mRNA and protein expression of both members were investigated in two independent breast cancer cohorts, we were unable to correlate directly between mRNA and protein expression in the current study.

mRNA-expression levels of each five RecQ DNA-helicase family members had different prognostic significance in breast cancer, which suggested that each RecQ helicase member has a particular biological function in breast cancer. However, the mechanisms of how each RecQ family member contributes to breast cancer remain unknown, even though each RecQ family member has been shown to have a key role in preserving genome stability by taking effects in DNA replication, recombination, DNA-damage signaling, DNA-repair pathways, and telomere maintenance.[@b6-cmar-10-6649],[@b22-cmar-10-6649],[@b23-cmar-10-6649]

RECQL is the smallest, but most abundant member of the human RecQ helicase family, and has been shown to be widely expressed in the cell nucleus.[@b24-cmar-10-6649],[@b25-cmar-10-6649] RECQL has been shown to be highly expressed in solid tumors, including glioblastoma,[@b26-cmar-10-6649] head and neck squamous-cell carcinoma,[@b27-cmar-10-6649] ovarian cancer,[@b28-cmar-10-6649] hepatocellular carcinoma,[@b29-cmar-10-6649] and squamous-cell carcinoma of the tongue.[@b30-cmar-10-6649] RECQL has also been shown to be expressed at high levels in non-small-cell lung cancer cell lines when compared with a normal bronchial epithelial cell line, and it has been proposed to have a role in lung cancer by regulating epithelial--mesenchymal transition.[@b31-cmar-10-6649] RECQL is significantly overexpressed in multiple myeloma cells when compared with normal plasma cells, and has been shown to be associated with poor prognosis.[@b9-cmar-10-6649] It has been hypothesized that tumors may depend on RECQL to tolerate replication-induced DNA damage. Recently, Arora et al showed that high *RECQL* mRNA expression was correlated with improved breast cancer-specific survival (BCSS) in patients with ER-positive breast cancer.[@b32-cmar-10-6649] However, in this present study, there was no correlation between the mRNA expression of *RECQL* and prognosis in ER-positive breast cancer, but increased mRNA expression of *RECQL* was associated with reduced RFS and PPS in all breast cancer patients and improved OS in patients with basal-like breast cancer, and mutant-p53-type breast cancer. The controversial findings could be due to different patient cohorts and limited patient populations.

BLM is focally located to promyelocytic leukemia bodies and telomeres in the cell nucleus.[@b33-cmar-10-6649],[@b34-cmar-10-6649] The expression of BLM varies in the cell cycle, and is increased in the S and G~2~/M phases.[@b35-cmar-10-6649] BLM is a critical helicase for DNA metabolism, replication, and repair.[@b6-cmar-10-6649] Mutation of *BLM* is associated with Bloom's syndrome, which is a rare and autosomal-recessive hereditary clinical disease that is characterized by proportional dwarfism, and which can be associated with the early development of several types of cancer.[@b36-cmar-10-6649] BLM is overexpressed in some tumor cells, and abnormalities in BLM are associated with genome instability, which has been shown in recent studies to lead to tumorigenesis.[@b11-cmar-10-6649]--[@b13-cmar-10-6649] Recently, Qian et al showed that BLM was overexpressed in prostate cancer cells and tissue compared with benign prostatic hyperplasia cells and nonprostate cancer tissue.[@b37-cmar-10-6649] In 2015, Arora et al showed that in breast cancer, overexpression of *BLM* mRNA was significantly correlated with increased histopathological grade, larger tumors, ER-negative tumors, PR-negative tumors, and triple-negative tumor phenotypes, and associated with reduced BCSS.[@b38-cmar-10-6649] BLM has a role in DNA replication and cell proliferation,[@b39-cmar-10-6649] which may be a reason for the presence of high *BLM* mRNA in invasive breast cancer. The results of this present study showed that high mRNA expression of *BLM* was correlated with reduced DMFS, although no significant associations were found between the mRNA expression of *BLM* and tumor grade, ER-negative, PR-negative, or triple-negative breast cancer status. These discrepant results might be due to different methods in determining cutoffs. Second, the number of patients in our study was relatively small.

WRN is located primarily in the nucleolus in normal cells, but after DNA damage it rapidly relocates to other nuclear regions.[@b40-cmar-10-6649]--[@b43-cmar-10-6649] The gene responsible for Werner's syndrome was recognized by positional cloning,[@b44-cmar-10-6649] and in addition to having 3′→5′ helicase activity, the WRN protein also has 3′→5′ exonuclease activity, unlike other RecQ DNA helicases.[@b6-cmar-10-6649] Loss of function of WRN can result in the clinical condition of Werner's syndrome, which is characterized by an increased incidence of tumors, including follicular thyroid carcinoma, malignant melanoma, and soft-tissue sarcoma.[@b45-cmar-10-6649]--[@b47-cmar-10-6649] The *WRN* gene plays an important role in DNA repair, replication, recombination, and maintenance of nuclear telomeres, which means that reduced expression of WRN results in genomic instability.[@b48-cmar-10-6649]--[@b50-cmar-10-6649] Malignant tumor cells might be able to increase WRN expression to protect the stability of their genome, as increased protein expression of WRN has been demonstrated in some cancer cell lines and knockdown of WRN to induce cell death.[@b51-cmar-10-6649] However, there have been few studies on the role of WRN in breast cancer. In this present study, the findings showed that high levels of *WRN* mRNA expression were significantly associated with increased patient OS and RFS and modestly associated with increased OS in ER-negative breast cancer patients. At the protein level, we observed high WRN levels in 44.1% of breast cancers, and similarly high WRN expression was correlated with increased OS. Research on WRN has primarily focused on in vitro study, and future clinical studies are needed to validate our findings.

RECQL4 is distributed in the nucleus and cytoplasm in different types of cells and tissue.[@b52-cmar-10-6649] RECQL4 is sometimes located in mitochondria, where it may have a role in preserving mitochondrial DNA integrity.[@b53-cmar-10-6649],[@b54-cmar-10-6649] Mutations in the *RECQL4* gene can lead to clinical disorders, including Rothmund--Thomson syndrome, which includes growth retardation and a predisposition to cancer, and the RAPADI-LINO syndrome.[@b52-cmar-10-6649] RECQL4 has been reported to be highly expressed in osteosarcoma cells[@b55-cmar-10-6649] and prostate cancer cells where tumor growth was shown to be reduced by siRNA-mediated suppression of RECQL4.[@b56-cmar-10-6649] Increased expression of RECQL4 has also been previously reported in breast cancer,[@b16-cmar-10-6649] laryngeal cancer,[@b57-cmar-10-6649] cervical cancer,[@b58-cmar-10-6649] and oral cancer.[@b59-cmar-10-6649] In a previous study, increased expression of *RECQL4* mRNA (51%), RecQL4 protein (23%), and *RECQL4* gene amplification (30.6%) were correlated with invasive tumor characteristics and poor survival in patients with breast cancer.[@b60-cmar-10-6649] Fang et al reported that RECQL4 might interact with survivin to regulate the survival of breast cancer cells.[@b16-cmar-10-6649]

The findings of the present study showed that high mRNA expression of *RECQL4* was significantly associated with decreased OS, DMFS, and RFS in patients with breast cancer and decreased OS in patients with luminal A-type breast cancer, HER2-positive, ER-positive, and PR-positive breast cancer. At the protein level, we observed high RECQL4 levels in 37.4% of breast cancers, and similarly high expression of RECQL4 was associated with increased OS. This current study was a retrospective study, and our results require confirmation in prospective studies with larger populations.

RECQL5 maintains the stability and integrity of the genome, but there are no reported hereditary diseases associated with defects in the *RECQL5* gene. However, *RECQL5* genetic polymorphisms have been reported to be associated with laryngeal carcinoma,[@b61-cmar-10-6649] osteosarcoma,[@b62-cmar-10-6649] and breast cancer.[@b63-cmar-10-6649] Studies have shown that expression of RECQL5 is decreased in colorectal cancer[@b64-cmar-10-6649] and osteosarcoma.[@b65-cmar-10-6649] In 2015, Wu et al reported that RECQL5 might have a role as a tumor suppressor in osteosarcoma and as a potential target for the treatment of osteosarcoma.[@b65-cmar-10-6649] In 2016, Patterson et al showed that RECQL5 was highly expressed in urothelial carcinoma of the bladder compared with normal bladder tissue and that overexpression of RECQL5 could promote the proliferation of normal bladder cells. In bladder cancer, increased expression of RECQL5 was associated with poor patient prognosis.[@b66-cmar-10-6649] RECQL5 maintains genomic stability by participating in many DNA metabolic processes including DNA repair.[@b67-cmar-10-6649] High levels of RECQL5 may promote the survival of cancer cells under DNA damage in established tumors. In a previous study in breast cancer, high mRNA-expression levels of *RECQL5* were significantly correlated with poor BCSS in a whole cohort of patients with breast cancer and particularly with an ER-positive subgroup.[@b17-cmar-10-6649] Conversely, the findings in this present study showed that increased mRNA expression of *RECQL5* was significantly associated with increased RFS, especially in lymph-node-negative patients, but with reduced OS in patients with HER2-positive breast cancer. The different findings between these two studies might be due to diverse patient populations, different follow-up times, and varied methods of data analysis.

Breast cancer is known to be a heterogeneous and complicated disease with many prognostic factors, and several potential prognostic clinicopathological features and molecular markers have been investigated.[@b68-cmar-10-6649] Currently, for patients who are diagnosed with breast cancer, the most important prognostic factors are axillary-node status, tumor size, and histological tumor grade.[@b69-cmar-10-6649] Because intrinsic breast cancer subtypes are also associated with clinical outcome, these were included in this study, as well as including the ER and PR status of the tumors. Low expression of *RECQL* mRNA has previously been shown to be associated with poor BCSS in patients with ER-positive breast cancer,[@b32-cmar-10-6649] and high *BLM* mRNA expression was previously reported to be correlated with poor BCSS in patients with ER-positive breast cancer and improved BCSS in patients with ER-negative breast cancer,[@b38-cmar-10-6649] while high *RECQL5* mRNA expression has previously been reported to be associated with poor BCSS in patients with ER-positive breast cancer.[@b17-cmar-10-6649] The mechanisms by which the five RecQ helicase members in human cells (RECQL, BLM, WRN, RECQL4, and RECQL5) are activated or inhibited by different hormones, genes, or environmental or epigenetic factors in breast cancer remain to be further investigated.

Conclusion
==========

The findings of this study showed that mRNA-expression levels of the five RecQ DNA helicase family members -- *RECQL*, *BLM*, *WRN*, *RECQL4*, and *RECQL5* -- were significantly correlated with prognosis in breast cancer patients. These preliminary findings require further study to determine whether diagnostic, prognostic, or therapeutic biomarker targets might be developed for clinical application in breast cancer.
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Data on associations of RecQ family-member mRNA expression with prognostic value can be downloaded from the online Kaplan--Meier Plotter breast cancer database (<http://kmplot.com/analysis/index.php>), and data sets used and analyzed during the current study are available from the corresponding author on reasonable request.
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###### 

OS curves of *BLM* with intrinsic different breast cancer subtypes identified for patients in the database (Affymetrix ID for *BLM*: 205733_at).

**Notes:** (**A**) Luminal A, (**B**) luminal B, (**C**) HER2, (**D**) basal-like.

**Abbreviation:** OS, overall survival.

###### 

OS curves of *WRN* with different intrinsic breast cancer subtypes identified for patients in the database (Affymetrix ID for *WRN*: 205667_at).

**Notes:** (**A**) Luminal A, (**B**) luminal B, (**C**) HER2, (**D**) basal-like.

**Abbreviation:** OS, overall survival.

###### 

Clinicopathological characteristics of WRN- and RECQL4-expression cohorts in tumor tissue

                    WRN   *P*-value   RECQL4   *P*-value        
  ----------------- ----- ----------- -------- ----------- ---- -------
                                                                
  **Age, years**                      0.931                     0.058
  \>50              35    45                   34          42   
  ≤50               32    40                   21          50   
  **Laterality**                      0.614                     0.082
  Left              28    39                   29          35   
  Right             39    46                   26          57   
  **T stage**                         0.273                     0.573
  T1                20    16                   11          20   
  T2                41    59                   40          60   
  T3                6     8                    4           10   
  Unknown           0     2                    0           2    
  **N stage**                         0.902                     0.414
  N0                27    31                   19          36   
  N1                22    26                   17          29   
  N2                14    20                   16          18   
  N3                3     5                    1           7    
  Unknown           1     3                    2           2    
  **AJCC stage**                      0.346                     0.893
  1                 8     5                    3           7    
  2                 40    48                   31          55   
  3                 18    28                   19          27   
  Unknown           1     4                    2           3    
  **ER status**                       0.205                     0.186
  Positive          42    60                   32          67   
  Negative          25    23                   22          24   
  Unknown           0     2                    1           1    
  **PR status**                       0.668                     0.638
  Positive          37    52                   31          57   
  Negative          29    31                   23          32   
  Unknown           1     2                    1           3    
  **HER2 status**                     0.447                     0.910
  Positive          16    20                   13          21   
  Negative          51    65                   42          71   

**Note:** Associations between protein-expression levels of WRN or RECQL4 and clinicopathological features analyzed using Pearson's χ^2^ test.

**Abbreviation:** AJCC, American Joint Committee on Cancer.
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![Survival curves of *RECQL* mRNA expression in all BCs from the database (Affymetrix ID for *RECQL*: 212918_at).\
**Notes:** (**A**) RFS curve; (**B**) PPS curve; (**C**) OS curve; (**D**) DMFS curve.\
**Abbreviations:** BC, breast cancer; RFS, relapse-free survival; PPS, postprogression survival; OS, overall survival; DMFS, distant metastasis-free survival.](cmar-10-6649Fig1){#f1-cmar-10-6649}

![Survival curves of *BLM* mRNA expression in all BCs from the database (Affymetrix ID for *BLM*: 205733_at).\
**Notes:** (**A**) DMFS curve; (**B**) OS curve; (**C**) RFS curve; (**D**) PPS curve.\
**Abbreviations:** BC, breast cancer; DMFS, distant metastasis-free survival; OS, overall survival; RFS, relapse-free survival; PPS, postprogression survival.](cmar-10-6649Fig2){#f2-cmar-10-6649}

![Survival curves of *WRN* mRNA expression in all BCs from the database (Affymetrix ID for *WRN*: 205667_at).\
**Notes:** (**A**) OS curve; (**B**) RFS curve; (**C**) DMFS curve; (**D**) PPS curve.\
**Abbreviations:** BC, breast cancer; OS, overall survival; RFS, relapse-free survival; DMFS, distant metastasis-free survival; PPS, postprogression survival.](cmar-10-6649Fig3){#f3-cmar-10-6649}

![Survival curves of *RECQL4* mRNA expression in all breast cancers from the database (Affymetrix ID for *RECQL4*: 213520_at).\
**Notes:** (**A**) OS curve; (**B**) DMFS curve; (**C**) RFS curve; (**D**) PPS curve.\
**Abbreviations:** BC, breast cancer; OS, overall survival; DMFS, distant metastasis-free survival; RFS, relapse-free survival; PPS, postprogression survival.](cmar-10-6649Fig4){#f4-cmar-10-6649}

![Survival curves of *RECQL5* mRNA expression in all BCs from the database (Affymetrix ID for *RECQL5*: 221686_s\_at).\
**Notes:** (**A**) RFS curve; (**B**) OS curve; (**C**) DMFS curve; (**D**) PPS curve.\
**Abbreviations:** BC, breast cancer; RFS, relapse-free survival; OS, overall survival; DMFS, distant metastasis-free survival; PPS, postprogression survival.](cmar-10-6649Fig5){#f5-cmar-10-6649}

![OS curves of *RECQL* with different intrinsic breast cancer subtypes identified for patients in the database (Affymetrix ID for *RECQL*: 212918_at).\
**Notes:** (**A**) Basal-like; (**B**) luminal A; (**C**) luminal B; (**D**) HER2.\
**Abbreviation:** OS, overall survival.](cmar-10-6649Fig6){#f6-cmar-10-6649}

![OS curves of *RECQL4* with the different intrinsic breast cancer subtypes identified for patients in the database (Affymetrix IDs for *RECQL4*: 213520_at).\
**Notes:** (**A**) Luminal A; (**B**) HER2; (**C**) Luminal B; (**D**) Basal-like.\
**Abbreviation:** OS, overall survival.](cmar-10-6649Fig7){#f7-cmar-10-6649}

![OS curves of *RECQL5* with the different intrinsic breast cancer subtypes identified for patients in the database (Affymetrix ID for *RECQL5*: 221686_s\_at).\
**Notes:** (**A**) HER2; (**B**) Luminal A; (**C**) Luminal B; (**D**) Basal-like.\
**Abbreviation:** OS, overall survival.](cmar-10-6649Fig8){#f8-cmar-10-6649}

![Prognostic significances of WRN and RECQL4 protein expression in breast cancer.\
**Notes:** (**A**) Immunohistochemical analysis of WRN in breast cancer tissue with low staining and high staining; (**B**) immunochemical analysis of RECQL4 in breast cancer tissue with low staining and high staining; (**C**) Kaplan--Meier OS analysis of WRN protein expression for patients with breast cancer; (**D**) Kaplan--Meier OS analysis of RECQL4 protein expression for patients with breast cancer. Each tissue section was observed under microscopy with low magnification of 50× and high magnification of 100×.\
**Abbreviation:** OS, overall survival.](cmar-10-6649Fig9){#f9-cmar-10-6649}

###### 

Correlation of RecQ-member mRNA expression with OS in different ER statuses of breast cancer patients

  RecQ family   Affymetrix ID   ER status   Cases        HR      95% CI       *P*-value
  ------------- --------------- ----------- ------------ ------- ------------ -----------
  *RECQL*       212918_at       Positive    548          1.14    0.80--1.63   0.46
  Negative      251             1.00        0.64--1.57   1.00                 
  *BLM*         205733_at       Positive    548          1.27    0.89--1.81   0.19
  Negative      251             1.13        0.79--1.61   0.51                 
  *WRN*         205667_at       Positive    548          1.13    0.79--1.61   0.51
  Negative      251             0.64        0.40--1.02   0.056                
  *RECQL4*      213520_at       Positive    548          1.90    1.33--2.74   \<0.001
  Negative      251             1.29        0.82--2.03   0.27                 
  *RECQL5*      221686_s\_at    Positive    548          0.97    0.68--1.39   0.88
  Negative      251             0.90        0.57--1.42   0.66                 

**Notes:** HR and 95% CI for OS presented as high vs low expression. HR \<1 indicates patients with high expression of each RecQ family achieving better OS than low expression.

**Abbreviation:** OS, overall survival; ER, estrogen receptor.

###### 

Correlation of RecQ-member mRNA expression with OS in different PR statuses of breast cancer patients

  RecQ family   Affymetrix ID   PR status   Cases        HR     95% CI        *P*-value
  ------------- --------------- ----------- ------------ ------ ------------- -----------
  *RECQL*       212918_at       Positive    83           2.90   0.60--14.05   0.17
  Negative      89              1.41        0.56--3.58   0.47                 
  *BLM*         205733_at       Positive    83           0.66   0.16--2.64    0.55
  Negative      89              1.10        0.44--2.78   0.84                 
  *WRN*         205667_at       Positive    83           0.81   0.22--3.01    0.75
  Negative      89              0.69        0.27--1.78   0.44                 
  *RECQL4*      213520_at       Positive    83           4.87   1.01--23.52   0.029
  Negative      89              0.58        0.23--1.51   0.26                 
  *RECQL5*      221686_s\_at    Positive    83           1.10   0.29--4.11    0.89
  Negative      89              3.20        1.14--8.97   0.02                 

**Notes:** HR and 95% CI for OS presented as high vs low expression. HR \<1 indicates patients with high expression of each RecQ family achieving better OS than low expression.

**Abbreviation:** OS, overall survival; PR, progesterone receptor.

###### 

Correlation of RecQ-member mRNA expression with OS in different lymph-node statuses of breast cancer patients

  RecQ family   Affymetrix ID   Lymph-node status   Cases        HR      95% CI       *P*-value
  ------------- --------------- ------------------- ------------ ------- ------------ -----------
  *RECQL*       212918_at       Positive            313          0.70    0.47--1.03   0.07
  Negative      594             1.26                0.87--1.83   0.22                 
  *BLM*         205733_at       Positive            313          1.05    0.72--1.55   0.79
  Negative      594             1.08                0.74--1.56   0.70                 
  *WRN*         205667_at       Positive            313          0.80    0.54--1.18   0.25
  Negative      594             0.92                0.63--1.34   0.65                 
  *RECQL4*      213520_at       Positive            313          1.30    0.88--1.92   0.18
  Negative      594             1.38                0.95--2.01   0.09                 
  *RECQL5*      221686_s\_at    Positive            313          1.28    0.86--1.89   0.22
  Negative      594             0.68                0.47--0.99   0.043                

**Notes:** HR and 95% CI for OS presented as high vs low expression. HR \<1 indicates patients with high expression of each RecQ family achieving better OS than low expression.

**Abbreviation:** OS, overall survival.

###### 

Correlation of RecQ-member mRNA expression with OS in different grades of breast cancer patients

  RecQ family   Affymetrix ID   Grade   Cases        HR     95% CI       *P*-value
  ------------- --------------- ------- ------------ ------ ------------ -----------
  *RECQL*       212918_at       I       161          2.02   0.77--5.25   0.14
  II            387             0.79    0.51--1.22   0.29                
  III           503             0.99    0.72--1.38   0.97                
  *BLM*         205733_at       I       161          1.08   0.43--2.66   0.88
  II            387             1.37    0.89--2.12   0.15                
  III           503             0.75    0.54--1.05   0.09                
  *WRN*         205667_at       I       161          1.06   0.41--2.74   0.91
  II            387             1.07    0.70--1.64   0.76                
  III           503             0.89    0.64--1.24   0.49                
  *RECQL4*      213520_at       I       161          0.83   0.33--2.05   0.68
  II            387             1.32    0.86--2.03   0.20                
  III           503             1.23    0.88--1.70   0.22                
  *RECQL5*      221686_s\_at    I       161          0.74   0.30--1.83   0.51
  II            387             1.30    0.85--2.01   0.22                
  III           503             0.88    0.63--1.22   0.44                

**Notes:** HR and 95% CI for OS presented as high vs low expression. HR \<1 indicates patients with high expression of each RecQ family achieving better OS than low expression.

**Abbreviation:** OS, overall survival.

###### 

Correlation of RecQ-member mRNA expression with OS in different *TP53* statuses of breast cancer patients

  RecQ family   Affymetrix ID   TP53 status   Cases        HR     95% CI       *P*-value
  ------------- --------------- ------------- ------------ ------ ------------ -----------
  *RECQL*       212918_at       Mutant        111          0.33   0.13--0.82   0.013
  Wild type     187             0.74          0.39--1.42   0.37                
  *BLM*         205733_at       Mutant        111          1.15   0.53--2.49   0.72
  Wild type     187             1.64          0.84--3.19   0.14                
  *WRN*         205667_at       Mutant        111          1.27   0.60--2.71   0.53
  Wild type     187             0.80          0.42--1.53   0.50                
  *RECQL4*      213520_at       Mutant        111          1.78   0.82--3.84   0.14
  Wild type     187             1.42          0.74--2.73   0.29                
  *RECQL5*      221686_s\_at    Mutant        111          1.33   0.59--2.98   0.49
  Wild type     187             1.71          0.88--3.32   0.11                

**Notes:** HR and 95% CI for OS presented as high vs low expression. HR \<1 indicates patients with high expression of each RecQ family achieving better OS than low expression.

**Abbreviation:** OS, overall survival.

[^1]: These authors contributed equally to this work
